<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367610</url>
  </required_header>
  <id_info>
    <org_study_id>2019/976</org_study_id>
    <nct_id>NCT04367610</nct_id>
  </id_info>
  <brief_title>Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection</brief_title>
  <official_title>Effects of A Standardized Treatment Approach Comprising Plasma Exchange, Intravenous Immunoglobulin and Rituximab on Kidney Transplant Recipients With Acute or Chronic Antibody-Mediated Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibody-mediated rejection (ABMR) is one of the leading causes of graft loss in kidney
      transplant recipients (KTRs). Although it is a well characterized entity, there is limited
      data regarding effective treatment options for preserving graft functions. Moreover, results
      from different studies have been contradictory. Therefore, we conducted a study using our
      registry data to evaluate the effects of a standardized treatment approach consisting of
      therapeutic plasma exchange (regular plasmapheresis, double filtration plasmapheresis or
      immunoadsorption), intravenous immunoglobulin and rituximab on KTRs with acute or chronic
      ABMR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Loss</measure>
    <time_frame>2-5 years</time_frame>
    <description>Returning to dialysis due to graft failure or death with a functioning graft.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Antibody-mediated Rejection</condition>
  <condition>Kidney Transplant Rejection</condition>
  <condition>Graft Loss</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Kidney transplant recipients with biopsy-proven acute or chronic antibody-mediated rejection who were treated using 6 sessions of therapeutic plasma exchange, 2 g/kg of intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2 rituximab.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant recipients with biopsy-proven acute or chronic antibody-mediated
        rejection who were treated using 6 sessions of therapeutic plasma exchange, 2 g/kg of
        intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2 rituximab.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being a kidney transplant recipient with biopsy-proven acute or chronic
             antibody-mediated rejection who were treated using 6 sessions of therapeutic plasma
             exchange, 2 g/kg of intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2
             rituximab.

        Exclusion Criteria:

          -  Not providing or withdrawing consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halil Yazici, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Safak Mirioglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Safak Mirioglu, MD</last_name>
    <phone>+902124142000</phone>
    <phone_ext>32149</phone_ext>
    <email>smirioglu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Halil Yazici, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Safak Mirioglu, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Halil Yazici, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Elif Aksoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ozan Yegit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014 Feb;14(2):255-71. doi: 10.1111/ajt.12589. Epub 2014 Jan 8. Review.</citation>
    <PMID>24401076</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Safak Mirioglu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>antibody-mediated rejection</keyword>
  <keyword>kidney transplantation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

